Kleinknecht D, Courouce A M, Delons S, Naret C, Adhemar J P, Ciancioni C, Fermanian J
Clin Nephrol. 1977 Sep;8(3):373-6.
In a controlled study, the protection effect of hepatitis B immune globulin (HBIG) was evaluated in patients hemodialyzed for less than one month in two collaborating units. Fifteen randomly selected patients received HBIG at five to eight week intervals throughout the study, and 13 other control patients received no immunoglobulin. During a follow-up period of 14 to 30 months, none of the HBIG-treated and 12 of the control patients developed evidence of exposure to virus B hepatitis, including 10 with HBs Ag antigenemia (p is less than 0.001): five of these remained persistently antigen positive. Evidence of non-B hepatitis was found in 8 HBIG-treated and in 3 non-treated patients. Only two HBIG-treated patients developed active antibodies against hepatitis B surface antigen. Thus, HBIG seems effective in preventing hepatitis B in hemodialysis patients, provided the interval between two injections is not greater than two months. However, prolonged administration of HBIG may impair passive-active immunization to hepatitis B virus.
在一项对照研究中，在两个合作单位对透析时间不足1个月的患者评估了乙肝免疫球蛋白（HBIG）的保护作用。在整个研究过程中，15名随机选择的患者每隔5至8周接受一次HBIG，另外13名对照患者未接受免疫球蛋白治疗。在14至30个月的随访期内，接受HBIG治疗的患者中无一例出现乙型肝炎病毒暴露的证据，而对照患者中有12例出现，包括10例HBs Ag抗原血症患者（p<0.001）：其中5例持续抗原阳性。在8例接受HBIG治疗的患者和3例未接受治疗的患者中发现了非乙型肝炎的证据。只有2例接受HBIG治疗的患者产生了抗乙肝表面抗原的活性抗体。因此，HBIG似乎对预防血液透析患者的乙型肝炎有效，前提是两次注射的间隔不超过两个月。然而，长期使用HBIG可能会损害对乙肝病毒的被动-主动免疫。
